Interacciones de Bromocriptina

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (etiqueta de Almotriptán, Contraindicaciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (etiqueta de Bupivacaína, Advertencias y precauciones)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (etiqueta de Bupivacaína y adrenalina, Advertencias y precauciones)

Use of bromocriptine, another dopamine agonist for this unapproved use has been associated with cases of hypertension, stroke, myocardial infarction, seizures, and death. (etiqueta de Cabergolina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (etiqueta de Cloroprocaína, Advertencias)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

• Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (etiqueta de Eletriptán, Contraindicaciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (etiqueta de Frovatriptán, Contraindicaciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (etiqueta de Lidocaína y adrenalina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (etiqueta de Mepivacaína, Advertencias)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

…Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (etiqueta de Naratriptán, Contraindicaciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (etiqueta de Nitroglicerina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (etiqueta de Rizatriptán, Contraindicaciones)

Also, there are limited clinical trial data supporting the safety of selective 5-hydroxytryptamine 1B (5-HT 1B ) agonists (e.g., sumatriptan) used concurrently with CYCLOSET, and the concomitant use of these agents with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Also, there are limited clinical trial data supporting the safety of selective 5-hydroxytryptamine 1B (5-HT 1B ) agonists (e.g., sumatriptan) used concurrently with CYCLOSET, and the concomitant use of these agents with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Tolcapone tablets is also contraindicated in patients with a history of nontraumatic rhabdomyolysis or hyperpyrexia and confusion possibly related to medication (see PRECAUTIONS: Events Reported With Dopaminergic Therapy ). (etiqueta de Tolcapona, Contraindicaciones)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etiqueta de Bromocriptina, Advertencias y precauciones)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (etiqueta de Zolmitriptán, Contraindicaciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The risk of hypertension is increased if bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity [see Contraindications (4)] . (etiqueta de Bupropión, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etiqueta de Bromocriptina, Advertencias y precauciones)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etiqueta de Deutetrabenazina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular fibrosis. (etiqueta de Dihidroergotamina, Advertencias)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etiqueta de Fenilefrina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Bromocriptine : Lanreotide Injection may increase the absorption of bromocriptine. (etiqueta de Lanreotida, Interacciones medicamentosas)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etiqueta de Bromocriptina, Advertencias y precauciones)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (etiqueta de Lidocaína, Interacciones medicamentosas)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (etiqueta de Linezolid, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etiqueta de Metilergometrina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Dopaminergic Drugs (levodopa and amantadine): CNS toxicity can occur when used concomitantly with CONTRAVE. (etiqueta de Naltrexona y bupropión, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Bromocriptine: Consider bromocriptine dose reduction. (etiqueta de Pasireotida, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring. (etiqueta de Primaquina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (etiqueta de Rasagilina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (etiqueta de Selegilina, Advertencias y precauciones)

• Drugs that could increase sirolimus blood concentrations: Bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors (e.g., HIV and hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir), metoclopramide, nicardipine, troleandomycin, verapamil • Drugs and other agents… (etiqueta de Sirolimus, Interacciones medicamentosas)

Drugs that Increase Blood Pressure and/or Heart Rate and Dopaminergic Drugs : Use caution when co-administering with SUNOSI. (etiqueta de Solriamfetol, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (etiqueta de Tetrabenazina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etiqueta de Valbenazina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Falling Asleep During Activities of Daily Living and Somnolence Patients taking carbidopa-levodopa products alone or with other dopaminergic drugs have reported suddenly falling asleep without prior warning of sleepiness while engaged in activities of daily living (includes operation of motor vehicles). (etiqueta de Carbidopa, Advertencias)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The expected incidence of these events, however, is so low that even if pramipexole caused these events at rates similar to those attributable to other dopaminergic therapies, it would be unlikely that even a single case would have occurred in a cohort of the size exposed to pramipexole in studies to date. (etiqueta de Pramipexol, Advertencias y precauciones)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (etiqueta de Ropinirol, Advertencias y precauciones)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)